Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced it will release results from its Phase 1a trial of anti-TSLP/IL-4R bispecific antibody ATI-052 and lead indication selection results for ITK/JAK3 inhibitor ATI-2138 on April 28, 2026, before market opening.

The Wayne, Pennsylvania-based clinical-stage biopharmaceutical company will host a webcast and conference call at 8:30 AM EST on April 28 to discuss the updates. The Phase 1a trial examined single and multiple ascending doses of ATI-052.

Aclaris focuses on developing treatments for immuno-inflammatory diseases. The company stated the webcast will be archived on its website for 30 days following the event.